title: Periprocedural and short-term outcomes of transfemoral transcatheter aortic valve implantation with the Sapien XT as compared with the Edwards Sapien valve.
abstract: OBJECTIVE
  The aim of this study was to analyze the short-term outcomes after transcatheter aortic valve implantation with the Edwards Sapien THV (ESV), compared with the Sapien XT THV (SXT) (Edwards Lifesciences, Irvine, California).
  
  
  BACKGROUND
  The SXT has been recently commercialized in Europe, but there are no studies analyzing the efficacy and safety of SXT, compared with ESV.
  
  
  METHODS
  All consecutive patients (n = 120) who underwent transcatheter aortic valve implantation in our center via the transfemoral approach with either ESV (n = 66) or SXT (n = 54). Valve Academic Research Consortium endpoints were used.
  
  
  RESULTS
  Mean age was 80 ± 8 years, and mean Logistic-European System for Cardiac Operative Risk Evaluation was 24.9 ± 17.0. The ilio-femoral artery minimal lumen diameter was smaller in patients treated with the SXT (7.27 ± 1.09 mm vs. 7.94 ± 1.08 mm, p = 0.002). Device success was high in both groups (96.3% vs. 92.4%, p = 0.45). Major vascular events were 3-fold lower in the SXT group (11.1% vs. 33.3%, relative risk: 0.40, 95% confidence interval: 0.28 to 0.57; p = 0.004). Life-threatening and major bleeding events were not significantly different between groups (18.5% vs. 27.3% and 35.2% vs. 40.9%, respectively). The SXT group had a lower 30-day Valve Academic Research Consortium combined safety endpoint (20.4% vs. 45.5%; relative risk: 0.44, 95% confidence interval: 0.24 to 0.80; p = 0.004). The 30-day mortality was 1.7% (n = 2). At 30 days, mean transaortic gradient was approximately 10 mm Hg in both groups and the aortic regurgitation was mild-to-moderate in 70.2% of SXT and 76.3% of ESV.
  
  
  CONCLUSIONS
  The new SXT valve has the same short-term performance as the ESV but seems to be associated with a lower risk of major vascular complications and thus has a broader clinical application.
authors.affiliation: Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Mussardo
authors.forename: Azeem
authors.initials: A
authors.lastname: Latib
authors.forename: Alaide
authors.initials: A
authors.lastname: Chieffo
authors.forename: Cosmo
authors.initials: C
authors.lastname: Godino
authors.forename: Alfonso
authors.initials: A
authors.lastname: Ielasi
authors.forename: Micaela
authors.initials: M
authors.lastname: Cioni
authors.forename: Kensuke
authors.initials: K
authors.lastname: Takagi
authors.forename: Giedrius
authors.initials: G
authors.lastname: Davidavicius
authors.forename: Matteo
authors.initials: M
authors.lastname: Montorfano
authors.forename: Francesco
authors.initials: F
authors.lastname: Maisano
authors.forename: Mauro
authors.initials: M
authors.lastname: Carlino
authors.forename: Annalisa
authors.initials: A
authors.lastname: Franco
authors.forename: Remo D
authors.initials: RD
authors.lastname: Covello
authors.forename: Pietro
authors.initials: P
authors.lastname: Spagnolo
authors.forename: Antonio
authors.initials: A
authors.lastname: Grimaldi
authors.forename: Ottavio
authors.initials: O
authors.lastname: Alfieri
authors.forename: Antonio
authors.initials: A
authors.lastname: Colombo
mesh_terms: D000369:Aged, 80 and over; D001024:Aortic Valve Stenosis / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D002406:Catheterization, Peripheral / Q000379:methods*; D017023:Coronary Angiography; D017548:Echocardiography, Transesophageal; D005260:Female; D005263:Femoral Artery; D005500:Follow-Up Studies; D019918:Heart Valve Prosthesis Implantation / Q000379:methods*; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D057234:Preoperative Period; D011474:Prosthesis Design; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D013997:Time Factors; D016896:Treatment Outcome